The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF).

Paul SandhuJann P OngVinay GargMustafa AltahaOlubenga BelloSewa R SingalSubodh VermaAndrew T YanKim A Connelly

Published in: Acta diabetologica (2021)

In this cohort of stable ambulatory patients with T2DM without heart failure, saxagliptin treatment was not associated with adverse ventricular remodeling over 6 months as assessed using CMR and biomarkers.

Keyphrases

left ventricular
heart failure
blood pressure
magnetic resonance imaging
cardiac resynchronization therapy
contrast enhanced
atrial fibrillation
computed tomography
magnetic resonance
combination therapy
metabolic syndrome
diffusion weighted imaging
skeletal muscle
acute heart failure
adverse drug